Text Size
32 studies found for:    PSMA

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Efficacy of Portion Size Measurement Aids
Conditions: Nutrition Assessment;   Obesity
Intervention: Behavioral: Portion Size Measurement Aids (PSMAs)
2 Active, not recruiting Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
3 Recruiting A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
4 Active, not recruiting PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Condition: Prostate Cancer
Intervention: Biological: Peptide Vaccine
5 Recruiting Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Condition: Prostate Cancer
Interventions: Biological: engineered autologous T cells;   Drug: cyclophosphamide
6 Active, not recruiting Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
7 Completed Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
8 Active, not recruiting Vaccine Therapy in Treating Patients With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: human prostate-specific membrane antigen plasmid DNA vaccine;   Biological: mouse prostate-specific membrane antigen plasmid DNA vaccine
9 Recruiting Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 18F-DCFBC
10 Recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Prostate Cancer
Intervention: Biological: Gene Modified T Cells
11 Active, not recruiting Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer
Condition: Suspected Primary Prostate Cancer
Intervention: Device: ProxiScan (scintigraphic rectal probe)
12 Active, not recruiting Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: 18F-DCFBC
13 Recruiting Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: 18F-DCFBC
14 Completed Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: recombinant interleukin-12
15 Completed Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Conditions: Ovarian;   Melanoma;   Renal;   Prostate;   Colorectal;   Endometrial Carcinoma;   Cervical Carcinoma;   Testicular Cancer;   Thyroid Cancer;   Small Cell Lung Carcinoma;   Mesothelioma;   Breast Carcinoma;   Esophageal Carcinoma;   Gastric Cancer;   Pancreatic Carcinoma;   Neuroendocrine Cancer;   Liver Cancer;   Gallbladder Cancer;   Biliary Tract Cancer;   Anal Carcinoma;   Bone Sarcomas;   Soft Tissue Sarcomas;   Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME
16 Not yet recruiting Imaging of Residual Tumor During Prostatectomy
Conditions: Prostate Cancer;   Prostatectomy
Intervention:
17 Enrolling by invitation Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint
Condition: Prostate Cancer
Intervention: Device: Proxiscan device
18 Terminated A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
Condition: Prostate Cancer
Intervention: Drug: 123I-MIP-1072
19 Withdrawn Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
Condition: Prostate Cancer
Intervention: Drug: Dendritic cell immunotherapy
20 Completed A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: 123-I-MIP-1072;   Drug: 111-In capromab pendetide
To Top

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
† Indicates status has not been verified in more than two years